C
CIN Terminal
Cannabis Investor News
A CanIDeal, Inc. Company
J
Live
Loading market data...
Expand
Symbol Name Exchange Last Change Volume Watch
Home › Markets › Loading…
MSON Equity

MSON

OTCMKTS · MSON

$26.54
—
Live Price
Price History 5 Years

Analyst Coverage

Cannabis Investor News in-house rating · cin-analyst-v1.0

Neutral Conviction 2/5
57/100 composite
Fundamentals82
Regulatory55
Market40
Editorial30
Composite · trailing 12 months

CIN rates MSOS Daily Bear ETF Neutral, with two-out-of-five conviction and a composite score in the high-50s. The rating sits firmly within the Neutral band. Fundamentals provide the principal support, scoring in the low-80s on exceptional revenue-growth and gross-margin subscores, while operating profitability, market-cap tier, and cash-runway measures contribute less. Regulatory factors rank in the mid-50s, supported by jurisdiction posture and a clean enforcement record but constrained by weak filing cadence. Market evidence scores 40 because no quote is available, and editorial evidence ranks at 30 amid no newsroom or brief activity. The resulting setup combines strong reported commercial metrics with limited market confirmation and a stretched financial condition.

Licensed fundamentals data show year-over-year revenue growth of roughly 44% and a gross margin slightly above 71%, explaining the 93.5 growth subscore and perfect gross-margin subscore. Those strengths do not extend below gross profit: operating margin remains negative at approximately 12.5%, EBITDA is negative by about $5.7 million, and net income reflects a loss near $14.5 million. Market capitalization stands around $462 million, while the cash-burn ratio is approximately 1.2%, supporting only moderate market-cap and cash-runway contributions. Primary regulatory filings show no recorded filing date and no regulatory events across either the 90-day or 180-day periods. Institutional pricing feeds provide no current quote, while CIN newsroom coverage records no relevant newsroom or brief hits. Filing cadence, price discovery, and operating losses therefore cap conviction despite strong top-line expansion and gross economics.

The forward catalyst is a conversion of the dominant fundamentals pillar from gross-profit strength into improved operating performance. Continued revenue expansion at the current broad pace, paired with preservation of the gross margin above 70%, would create operating leverage and reinforce the strongest pillar without implying that stretched finances have normalized. Better filing cadence could improve regulatory support, but it remains secondary to the earnings structure. The single most important signal to watch is whether the negative operating margin begins narrowing while gross-margin strength holds.

Scored: 2026-10-14Valid through: 2026-11-28Weights: Fundamentals 35% · Regulatory 25% · Market 25% · Editorial 15%
Loading CIN Rating…
Fundamentals SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
Institutional DetailIR, corporate, and filing data from CIN enrichment
IR & AgencyInvestor relations
Corporate DetailsCompany profile
CEO
Noah Hamman
CFO
Dan Ahrens
SEC CIK
0000880432
Website
Company website
Fundamentals & FinancialsRefreshed nightly from licensed fundamentals data
Market cap
$462.5M
Enterprise value
$478.5M
Price to book
3.42
Price to sales
6.25
Revenue (TTM)
$74.0M
Gross profit (TTM)
$52.6M
EBITDA
$-5.7M
Operating margin
-12.5%
Profit margin
-19.6%
Rev growth YoY
43.5%
Return on equity
-10.3%
Return on assets
-2.9%
EPS (TTM)
$-0.84
EPS est. current year
$-0.95
Wall St. target price
$28.00
Shares outstanding
17.4M
Insider ownership
20.9%
Institutional ownership
41.0%
Beta
1.35
Full-time employees
281
GICS sector
Healthcare
GICS industry
Medical Devices
Filings & DisclosuresPrimary sources
Filing portal
SEC EDGAR
See something incorrect or missing?

Help us keep coverage accurate. Submit an update for CIN editorial review.

Submit an update
Complimentary Research
Would you like a deeper analysis on this company?

Request a complimentary, fully customized institutional-quality research report — tailored to your investment thesis.

Request Complimentary Report

Bullish and Bearish Analyst Opinions for MSON (MSON)

Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for MSON (MSON), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.

CIN editorial stance: Event-Driven Opportunity. Setup improving. Long-term outperformer detected. (2 bullish signals, 0 bearish signals.)

Historical Price Data

5-year weekly price history, intraday quotes, and 52-week range for MSON are maintained by Cannabis Investor News and refreshed throughout the trading day.